Esperion Therapeutics (ESPR)
(Delayed Data from NSDQ)
$1.68 USD
-0.07 (-4.00%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.68 0.00 (0.00%) 5:10 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Esperion Therapeutics, Inc. [ESPR]
Reports for Purchase
Showing records 1 - 20 ( 166 total )
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
2Q24 Results; BDA Gains Momentum With a Focused Sales Execution
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
New Royalty Agreement in Place Following BDA Label Expansion Approval in Europe
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Label Expansion Gets the Green Light in Europe; Key Execution Phase Now
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
BDA Succeeds in Reducing LDL-C in Japanese Phase 3 Trial; JNDA in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
1Q24 Results; U.S. Label Expansions Show Initial Signs of Increased Sales Traction; Potential European Approval in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Company: Esperion Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department